Heart failure & cardiomyopathiesCohort study
Prevalence, Characteristics and Cardiovascular and Non-Cardiovascular Outcomes in Patients with Heart Failure with Supra-Normal Ejection Fraction: Insight from the JROADHF Study
- Prospective registry cohort study
- nationwide registry
- multicentre
Authors' conclusion
Heart failure with supra-normal ejection fraction is a common and distinctive phenotype, and has different characteristics and prognoses from HFnEF.
Study context
- Population
- Patients hospitalised with heart failure (HF), nationwide registry in Japan (JROADHF)
- Participants
- 11,573 patients
- Exposure
- HFsnEF vs HF with normal ejection fraction (HFnEF)
- Outcome
- Composite of:
- CV death
- HF readmission
- Follow-up
- Median 870 days
Main finding
CV death or HF readmission · median 870 days
Hazard ratio
0.96
95% CI 0.88–1.05
P = 0.346
Events by group
HFsnEF vs HFnEF
HR 0.96 (95% CI 0.88–1.05); P = 0.346
As reported in the abstract
Observational data: associations, not effects.
Secondary outcomes
All-cause, CV and non-CV death; HF readmission
- Incidence did not differ between HFsnEF and HFnEF
Multivariable Cox regression
- HFsnEF vs HFnEF associated with lower adjusted HR for HF readmission, but not with the primary and other secondary endpoints
Subgroups (women; renal dysfunction)
- HFsnEF associated with higher HR for the composite endpoint and all-cause death in women
- HFsnEF associated with higher HR for all-cause death in patients with renal dysfunction
Characteristics, HFsnEF vs HFnEF
- HFsnEF older, more often women, lower natriuretic peptides, smaller LV
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Prevalence, Characteristics and Cardiovascular and Non-Cardiovascular Outcomes in Patients with Heart Failure with Supra-Normal Ejection Fraction: Insight from the JROADHF Study. Eur J Heart Fail. Published 4 June 2023. doi:10.1002/ejhf.2895
Summarised from the published abstract; every number is checked against it